Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07446959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Minimum Effective Volume of Bupivacaine for Serratus Posterior Superior Intercostal Plane Block in Video-Assisted Thoracoscopic Surgery

Study acronym: SPSIP-EV50
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Trial completed
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 56 words
    • Site details revised
  2. Primary completion moved earlier from Jul 15, 2026 to May 11, 2026v3
  3. Recruitment opened
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study determined the median effective volume (EV50) of bupivacaine required for the serratus posterior superior intercostal plane (SPSIP) block in patients undergoing video-assisted thoracoscopic surgery (VATS). The SPSIP block is an ultrasound-guided regional anesthesia technique used to provide postoperative pain relief after thoracic surgery. All patients received bupivacaine at a final concentration of 0.25%, prepared by diluting the commercially available 0.5% preparation 1:1 with 0.9% sodium chloride. Using a sequential up-and-down dose-adjustment method, the volume of local anesthetic was increased or decreased according to the block outcome of the preceding patient. The main outcome of the study was the volume that provided an effective block in 50% of patients. EV50 is not a recommended clinical dose; the results are intended to inform future studies targeting higher effective percentiles.
Trial Details
NCT Number NCT07446959
Lead Sponsor Bursa City Hospital
Collaborators: Ulusoy, Emre, M.D.
Conditions
(from sponsor)		 Postoperative Pain Management, Video-assisted Thoracoscopic Surgery (VATS)
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov